ESR1 and breast carcinoma: However, about half of the patients treated by endocrine therapy will eventually relapse, which makes it a significant clinical problem.7 Thus, further understanding of the underlying mechanisms and insights into new components of ERɑ signalling is critical in dealing with endocrine resistance in patients with breast cancer.